Cargando…
Antidepressants in paediatric depression: do not look back in anger but around in awareness
SUMMARY: In this paper, we summarise and critique a network meta-analysis (NMA) of antidepressant efficacy and tolerability for paediatric depression and an accompanying editorial. Although we agree that many of the extant studies are flawed, this meta-analysis showed clear efficacy of fluoxetine in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001874/ https://www.ncbi.nlm.nih.gov/pubmed/29388523 http://dx.doi.org/10.1192/bjb.2017.2 |
_version_ | 1783332098200829952 |
---|---|
author | Brent, David A. Gibbons, Robert D. Wilkinson, Paul Dubicka, Bernadka |
author_facet | Brent, David A. Gibbons, Robert D. Wilkinson, Paul Dubicka, Bernadka |
author_sort | Brent, David A. |
collection | PubMed |
description | SUMMARY: In this paper, we summarise and critique a network meta-analysis (NMA) of antidepressant efficacy and tolerability for paediatric depression and an accompanying editorial. Although we agree that many of the extant studies are flawed, this meta-analysis showed clear efficacy of fluoxetine in the NMA, and for sertraline and escitalopram in pairwise analyses. Consequently, these papers underestimate the benefits of antidepressants for paediatric depression, and provide support for current practice guideline, which recommends the use of an antidepressant if the patient does not respond to psychotherapy. In these circumstances, fluoxetine should be the first choice, with escitalopram and sertraline as alternatives. DECLARATION OF INTEREST: D.A.B. receives royalties from Guilford Press, has or will receive royalties from the electronic self-rated version of the C-SSRS from eResearch Technology, Inc., is on the editorial board of UpToDate, and is a reviewer for Healthwise. R.D.G. serves as an expert witness for the US Department of Justice, Pfizer, Wyeth and GSK; and is the founder of Adaptive Testing Technologies. P.W. receives personal fees from Lundbeck and Takeda. B.D. reports a licensing agreement with Lundbeck for a psychosocial treatment manual for depression. No other disclosures were reported. |
format | Online Article Text |
id | pubmed-6001874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60018742018-06-15 Antidepressants in paediatric depression: do not look back in anger but around in awareness Brent, David A. Gibbons, Robert D. Wilkinson, Paul Dubicka, Bernadka BJPsych Bull Editorial SUMMARY: In this paper, we summarise and critique a network meta-analysis (NMA) of antidepressant efficacy and tolerability for paediatric depression and an accompanying editorial. Although we agree that many of the extant studies are flawed, this meta-analysis showed clear efficacy of fluoxetine in the NMA, and for sertraline and escitalopram in pairwise analyses. Consequently, these papers underestimate the benefits of antidepressants for paediatric depression, and provide support for current practice guideline, which recommends the use of an antidepressant if the patient does not respond to psychotherapy. In these circumstances, fluoxetine should be the first choice, with escitalopram and sertraline as alternatives. DECLARATION OF INTEREST: D.A.B. receives royalties from Guilford Press, has or will receive royalties from the electronic self-rated version of the C-SSRS from eResearch Technology, Inc., is on the editorial board of UpToDate, and is a reviewer for Healthwise. R.D.G. serves as an expert witness for the US Department of Justice, Pfizer, Wyeth and GSK; and is the founder of Adaptive Testing Technologies. P.W. receives personal fees from Lundbeck and Takeda. B.D. reports a licensing agreement with Lundbeck for a psychosocial treatment manual for depression. No other disclosures were reported. Cambridge University Press 2018-02 /pmc/articles/PMC6001874/ /pubmed/29388523 http://dx.doi.org/10.1192/bjb.2017.2 Text en © The Authors 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial Brent, David A. Gibbons, Robert D. Wilkinson, Paul Dubicka, Bernadka Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title | Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title_full | Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title_fullStr | Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title_full_unstemmed | Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title_short | Antidepressants in paediatric depression: do not look back in anger but around in awareness |
title_sort | antidepressants in paediatric depression: do not look back in anger but around in awareness |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001874/ https://www.ncbi.nlm.nih.gov/pubmed/29388523 http://dx.doi.org/10.1192/bjb.2017.2 |
work_keys_str_mv | AT brentdavida antidepressantsinpaediatricdepressiondonotlookbackinangerbutaroundinawareness AT gibbonsrobertd antidepressantsinpaediatricdepressiondonotlookbackinangerbutaroundinawareness AT wilkinsonpaul antidepressantsinpaediatricdepressiondonotlookbackinangerbutaroundinawareness AT dubickabernadka antidepressantsinpaediatricdepressiondonotlookbackinangerbutaroundinawareness |